Price$19.95+1.11 (+5.89%)
01:30 PM07:45 PM
News · 26 weeks64+20%
2025-11-022026-04-26
Mix4090d
- Insider12(30%)
- SEC Filings9(23%)
- Other8(20%)
- Analyst8(20%)
- Earnings3(8%)
Latest news
25 items- SECuniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and analysis plan for AMT-130 four-year data ~ ~ uniQure actively pursuing additional ex-US regulatory pathways to support potential registration of AMT-130 in international markets ~ LEXINGTON, Mass. and AMSTERDAM, April 30, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the Company held a Pre-Submission Meeting with the United Kingdom's (UK) Medici
- PRuniQure to Announce First Quarter 2026 Financial Results~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2026 financial results before market open on Tuesday, May 5, 2026. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and
- SECSEC Form DEFA14A filed by uniQure N.V.DEFA14A - uniQure N.V. (0001590560) (Filer)
- SECSEC Form DEF 14A filed by uniQure N.V.DEF 14A - uniQure N.V. (0001590560) (Filer)
- SECSEC Form PRE 14A filed by uniQure N.V.PRE 14A - uniQure N.V. (0001590560) (Filer)
- ANALYSTuniQure upgraded by Mizuho with a new price targetMizuho upgraded uniQure from Neutral to Outperform and set a new price target of $35.00
- INSIDERChief Customer & Strat Officer O'Keefe Kylie was granted 19,800 units of Ordinary Shares, increasing direct ownership by 19% to 124,800 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERNew insider O'Keefe Kylie claimed ownership of 105,000 units of Ordinary Shares (SEC Form 3)3 - uniQure N.V. (0001590560) (Issuer)
- ANALYSTuniQure upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded uniQure from Sector Perform to Outperform and set a new price target of $35.00
- ANALYSTuniQure upgraded by Wells Fargo with a new price targetWells Fargo upgraded uniQure from Equal Weight to Overweight and set a new price target of $60.00
- INSIDERCEO, Managing Director Kapusta Matthew C was granted 70,600 units of Ordinary Shares and sold $132,104 worth of Ordinary Shares (14,581 units at $9.06), increasing direct ownership by 9% to 660,658 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Medical Officer Abi-Saab Walid sold $7,320 worth of Ordinary Shares (808 units at $9.06) and was granted 41,700 units of Ordinary Shares, increasing direct ownership by 27% to 189,669 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Legal Officer Potts Jeannette was granted 35,400 units of Ordinary Shares and sold $30,913 worth of Ordinary Shares (3,412 units at $9.06), increasing direct ownership by 30% to 138,483 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Financial Officer Klemt Christian was granted 39,600 units of Ordinary Shares and sold $108,720 worth of Ordinary Shares (12,000 units at $9.06), increasing direct ownership by 14% to 226,581 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERCEO, Managing Director Kapusta Matthew C sold $342,648 worth of Ordinary Shares (34,437 units at $9.95), decreasing direct ownership by 5% to 604,639 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Financial Officer Klemt Christian sold $124,693 worth of Ordinary Shares (12,532 units at $9.95), decreasing direct ownership by 6% to 198,981 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Legal Officer Potts Jeannette sold $85,351 worth of Ordinary Shares (8,578 units at $9.95), decreasing direct ownership by 7% to 106,495 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Medical Officer Abi-Saab Walid sold $16,517 worth of Ordinary Shares (1,660 units at $9.95), decreasing direct ownership by 1% to 148,777 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- ANALYSTuniQure downgraded by Wells Fargo with a new price targetWells Fargo downgraded uniQure from Overweight to Equal Weight and set a new price target of $15.00
- ANALYSTuniQure downgraded by Mizuho with a new price targetMizuho downgraded uniQure from Outperform to Neutral and set a new price target of $12.00
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- ANALYSTuniQure downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded uniQure from Outperform to Sector Perform and set a new price target of $11.00
- ANALYSTuniQure downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded uniQure from Overweight to Neutral and set a new price target of $9.00
QURE FAQ
7 questionsWhat does uniQure N.V. do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated...Where does QURE stock trade?
uniQure N.V. (QURE) is listed on NASDAQ.What sector and industry is QURE in?
uniQure N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did uniQure N.V. go public?
uniQure N.V. (QURE) completed its IPO in 2014.What are analysts saying about QURE?
uniQure N.V. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Outperform with a $3500.00 price target on 2026-03-11. Recent price targets range from $900.00 to $3500.00.What companies are similar to QURE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare QURE side-by-side with any of them on Quantisnow.How can I track QURE on Quantisnow?
Quantisnow aggregates uniQure N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QURE to receive live email and push alerts on every new disclosure.